University of Chicago, Chicago, Illinois.
Center of Excellence for Suicide Prevention, Department of Veterans Affairs, Canandaigua, New York.
JAMA Psychiatry. 2022 Nov 1;79(11):1118-1123. doi: 10.1001/jamapsychiatry.2022.2990.
Suicide is a leading cause of death in the United States, having increased more than 30% from 2000 to 2018. An inexpensive, safe, widely available treatment for preventing suicidal behavior could reverse this trend.
To confirm a previous signal for decreased risk of suicide attempt following prescription fills for folic acid in a national pharmacoepidemiologic study of patients treated with folic acid.
DESIGN, SETTING, AND PARTICIPANTS: A within-person exposure-only cohort design was used to study the dynamic association between folic acid (vitamin B9) prescription fills over a 24-month period and suicide attempts and intentional self-harm. Data were collected from a pharmacoepidemiologic database of US medical claims (MarketScan) for patients with private health insurance who filled a folic acid prescription between 2012 and 2017. The same analysis was repeated with a control supplement (cyanocobalamin, vitamin B12). Data were analyzed from August 2021 to June 2022.
Folic acid prescription fills.
Suicide attempt or intentional self-harm resulting in an outpatient visit or inpatient admission as identified by codes from the International Statistical Classification of Diseases, Ninth and Tenth Revisions, Clinical Modification.
Data on 866 586 patients were collected; 704 514 (81.30%) were female, and 90 296 (10.42%) were 60 years and older. Overall, there were 261 suicidal events during months covered by a folic acid prescription (5 521 597 person-months) for a rate of 4.73 per 100 000 person-months, compared with 895 suicidal events during months without folic acid (8 432 340) for a rate of 10.61 per 100 000 person-months. Adjusting for age and sex, diagnoses related to suicidal behavior, diagnoses related to folic acid deficiency, folate-reducing medications, history of folate-reducing medications, and history of suicidal events, the hazard ratio (HR) for folic acid for suicide events was 0.56 (95% CI, 0.48-0.65), with similar results for the modal dosage of 1 mg of folic acid per day (HR, 0.57; 95% CI, 0.48-0.69) and women of childbearing age (HR, 0.60; 95% CI, 0.50-0.73). A duration-response analysis (1-mg dosage) revealed a 5% decrease in suicidal events per month of additional treatment (HR, 0.95; 95% CI, 0.93-0.97). The same analysis for the negative control, cyanocobalamin, found no association with suicide attempt (HR, 1.01; 95% CI, 0.80-1.27).
This large-scale pharmacoepidemiologic study of folic acid found a beneficial association in terms of lower rates of suicide attempts. The results warrant the conduct of a randomized clinical trial with suicidal ideation and behavior as outcomes of interest. If confirmed, folic acid may be a safe, inexpensive, and widely available treatment for suicidal ideation and behavior.
自杀是美国的主要死亡原因之一,自 2000 年至 2018 年,自杀率上升了 30%以上。一种廉价、安全、广泛可用的预防自杀行为的治疗方法可能会扭转这一趋势。
在一项针对接受叶酸治疗的患者的全国药物流行病学研究中,确认先前在开具叶酸处方后自杀企图风险降低的信号。
设计、地点和参与者:使用个体内暴露仅队列设计,研究了在 24 个月期间叶酸(维生素 B9)处方与自杀企图和自残之间的动态关联。数据来自美国医疗索赔(MarketScan)药物流行病学数据库,该数据库包含了 2012 年至 2017 年期间服用叶酸处方的私人医疗保险患者。使用控制补充剂(氰钴胺素,维生素 B12)重复了相同的分析。数据分析于 2021 年 8 月至 2022 年 6 月进行。
叶酸处方。
自杀企图或自残导致门诊就诊或住院治疗的情况,通过国际疾病分类、第九和第十次修订版的临床修正版的代码确定。
共收集了 866586 名患者的数据;704514 名(81.30%)为女性,90296 名(10.42%)为 60 岁及以上。总体而言,在服用叶酸的月份(5521597 人月)中,有 261 例自杀事件,每 100000 人月的发生率为 4.73,而在没有叶酸的月份(8432340 人月)中,有 895 例自杀事件,每 100000 人月的发生率为 10.61。调整年龄和性别、自杀行为相关诊断、叶酸缺乏相关诊断、叶酸还原药物、叶酸还原药物史和自杀事件史后,叶酸与自杀事件的风险比(HR)为 0.56(95%CI,0.48-0.65),每天 1 毫克叶酸的模式剂量也有类似的结果(HR,0.57;95%CI,0.48-0.69),育龄妇女(HR,0.60;95%CI,0.50-0.73)。持续时间反应分析(1 毫克剂量)显示,每月额外治疗可使自杀事件减少 5%(HR,0.95;95%CI,0.93-0.97)。对负对照氰钴胺素的相同分析发现,其与自杀企图无关联(HR,1.01;95%CI,0.80-1.27)。
这项大规模的叶酸药物流行病学研究发现,较低的自杀企图率与叶酸呈正相关。研究结果支持进行以自杀意念和行为为研究结果的随机临床试验。如果得到证实,叶酸可能是一种安全、廉价且广泛可用的治疗自杀意念和行为的方法。